Robert Orlowski, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses advances in myeloma treatment with Chadi Nabhan, MD, MBA, FACP, during the 2022 ASH Annual Meeting. Dr. Orlowski and Dr. Nabhan discussed bispecific antibodies, novel targets, the role of minimal residual disease in clinical practice, and more.